BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. on December 15, 2027. There is 1 upcoming event on record.
Cash runway is approximately 8.9 months based on the most recent reported cash position and quarterly operating burn as of 2026-04-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 15, 2027 | Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | Trial Milestone | Phase 3 |
Track BCTX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open BCTX in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| June 26, 2026 | 8-K filed: Reg FD disclosure | Filing | — |
| June 3, 2026 | 8-K filed: Material agreement, Other event | Corporate | — |
| March 31, 2026 | 8-K filed: Reg FD disclosure | Filing | — |
| March 24, 2026 | Combination Study of SV-BR-1-GM With Retifanlimab | Trial Milestone | Phase 1/Phase 2 |
| February 20, 2026 | 8-K filed: Other event | Filing | — |
| January 15, 2026 | 8-K filed: Material agreement, Other event | Corporate | — |
| December 29, 2025 | 8-K filed: Reg FD disclosure | Filing | — |
| December 1, 2025 | 8-K filed: Reg FD disclosure | Filing | — |
| August 26, 2025 | 8-K filed: Other event | Filing | — |
| July 16, 2025 | 8-K filed: Material agreement, Other event | Corporate | — |
| June 18, 2025 | 8-K filed: Reg FD disclosure | Filing | — |
| April 28, 2025 | 8-K filed: Material agreement, Other event | Corporate | — |
| November 22, 2018 | SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer | Trial Milestone | Phase 1/Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.